Novartis Not Tempted To Join COVID-19 Vaccines Race

No Longer Has Capabilities After GSK Asset Swap

21 Jul 2020

While the traditional players such as Pfizer and GSK, as well as newcomer AstraZeneca, are hot in pursuit of a COVID-19 vaccine, the Swiss major is sticking to drugs, the area where "we do have deep expertise," CEO Vas Narasimhan told journalists.

Doctor, nurse, scientist hand in blue gloves holding flu, measles, coronavirus, covid-19 vaccine disease preparing for child, baby, adult, man and woman vaccination shot, medicine and drug concept. — Novartis not returning to vaccine development • Source: Shutterstock

While most of the world's attention is on developing a safe and effective coronavirus vaccine, Novartis AG, which exited the space five years ago, has confirmed that it has no intention of going back in.

Having been a major player in vaccines, the Swiss major got out of the field after a $20bn asset swap...